Ovarian tumors of low malignant potential: Correlation of DNA index and S-phase fraction with histopathologic grade and clinical outcome

Cancer

Volumn 77, Issue 8, 1996, Pages 1494-1500

  Demirel, Dilaver ^a,b   Laucirica, Rodolfo ^a,d   Fishman, Amiram ^a,c   Owens, Robert G ^a   Grey, Marjorie M ^a   Kaplan, Alan L ^a   Ramzy, Ibrahim ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^c MEIR MEDICAL CENTER   (Israel)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

DNA index; Low malignant potential; Ovarian tumors; S phase fraction

Indexed keywords

ADULT; AGED; ANEUPLOIDY; ARTICLE; DIPLOIDY; DNA CONTENT; DNA DETERMINATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MITOSIS RATE; OVARY TUMOR; PLOIDY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CELL DIVISION; DIPLOIDY; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; PROGNOSIS; S PHASE;

EID: 0029866760     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960415)77:8<1494::AID-CNCR11>3.0.CO;2-V     Document Type: Article

References (38)

1. Ayhan A, Akarin R, Develioglu O, Yarali H, Kucukali T, Bilgin F. Borderline epithelial ovarian tumors. Aust N Z J Obstet Gynaecol 1991;31:174-6.
2. Nikrui N. Survey of clinical behavior of patients with borderline epithelial tumors of the ovary. Gynecol Oncol 1981;12:107-19.
3. Russell P. The pathological assessment of ovarian neoplasms. I. Introduction to the common "epithelial" tumors and analysis of benign "epithelial" tumors. Pathology 1979;11:5-26.
4. Bostwick DG, Tazelaar HD, Ballon SC, Hendrickson MR, Kempson RL. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 1986;58:2052-65.
5. Hart W, Norris HJ. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer 1973;31:1031-45.
6. Lauchlan SC. Non-invasive ovarian carcinoma. Int J Gynecol Pathol 1990;9:158-69.
7. Snyder RR, Norris HI, Tavassoli F. Endometrioid proliferative and low malignant potential tumors of the ovary. A clinicopathologic study of 46 cases. Am J Surg Pathol 1988;12:661-71.
8. Purola E. Serous papillary ovarian tumors: study of 233 cases with special reference to the histological type of tumor and its influence in prognosis. Acta Obstet Gynecol Scand 1963;42(Suppl 3).
9. Colgan T, Norris HJ. Ovarian epithelial tumors of low malignant potential: a review. Int J Gynecol Pathol 1983;1:367-82.
10. Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 1993;12:120-7.
11. Guthrie D, Davy MLJ, Philips PR. A study of 656 patients with "early" ovarian cancer. Gynecol Oncol 1984;17:363-9.
12. Powlis WD, Manch P, Ehrmann RL, Rose CM, Knapp RC, Bloomer WD. The role of post-operative local or regional irradiation in the treatment of Stage I ovarian cancer. Ther Radiol 1982;142:747-50.
13. Friedlander ML, Russell P, Taylor IW, Hedley DW, Tattersall MHN. Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumors of borderline malignancy. Pathology 1984;16:301-6.
14. Kaern J, Tropé C, Kjorstad KE, Abeler V, Pettersen EO. Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. Gynecol Oncol 1990;38:452-7.
15. Seidman JD, Norris HJ, Griffin JL, Hitchcock CL. DNA flow cytometric analysis of serous ovarian tumors of low malignant potential. Cancer 1993;71:3947-51.
16. Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329:1550-9.
17. Serov SF, Scully RE, Sobin LH. International histologic classification of tumors No. 9: histologic typing of ovarian tumors. Geneva: Worlk Health Organization, 1973:17-54.
18. Baak JPA, Van Dop H, Kurver PHJ, Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985;56:374-82.
19. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer 1988;62:2212-22.
20. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method of analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983;31:1333-5.
21. Vindelov LL, Christensen IJ, Nissen NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7.
22. Shankey W, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW, et al. Guidelines for implementation of clinical DNA cytometry. Cytometry 1993;14:472-7.
23. Rosner B. Fundamentals of Statistics. 3rd ed. Boston: PWS-KENT, 1990:336-41, 440-8, 474-515.
24. Friedlander ML, Hedley DW, Taylor IW, Russell P, Coates AS, Tattersall MHN. Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res 1984; 44:397-400.
25. Friedlander ML, Hedley DW, Russell P. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol 1988;6:282-90.
26. Hedley DW, Friedlander ML, Taylor IW. Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploid and its clinical significance. Cytometry 1985;4:327-33.
27. Iversen OE. Prognostic value of the flow cytometric DNA index in human ovarian carcinoma. Cancer 1988;61:971-5.
28. Kallioniemi OP, Punnonen R, Mattila J, Lehtinen M, Koivula T. Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer. Cancer 1988;61:334-9.
29. Brescia RJ, Barakat RA, Beller U, Frederickson G, Suhrland MJ, Dubin N, et al. The prognostic significance of nuclear DNA content in malignant epithelial tumors of the ovary. Cancer 1990;65:141-7.
30. Klemi PJ, Joensuu H, Kiiholma P, Maenpaa J. Clinical significance of abnormal nuclear DNA content in serous ovarian tumors. Cancer 1988;62:2005-10.
31. Kotylo PK, Michael H, Fineberg N, Sutton G, Roth LM. Flow cytometric analysis of DNA content and RASP21 oncoprotein expression in ovarian neoplasms. Int J Gynecol Pathol 1992;11:30-7.
32. Padberg BC, Arps H, Franke U, Thiedemann C, Rehpenning W, Stegner H-E, et al. DNA cytophotometry and prognosis in ovarian tumors of borderline malignancy. Cancer 1992; 69:2510-4.
33. Nictolis M, Montironi R, Tommasoni S, Carinelli S, Ojeda B, Matias-Guiu X, et al. Serous borderline tumors of the ovary. Cancer 1992;70:152-60.
34. Fu YS, Ro J, Reagan JW, Hall TL, Berek J. Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumors. Obstet Gynecol 1986;67:478-82.
35. Kuhn W, Kaufmann M, Feichter GE, Rummel HH, Schmid H, Heberling D. DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors. Gynecol Oncol 1989;33:360-7.
36. Kaern J, Trope CG, Kristensen GB, Abeler VM, Pettersen EO. DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 1993;3:349-58.
37. Clark GM, Mathieu M-C, Owens MA, Dressler LG, Eudey L, Tormey DC, et al. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 1922;10:428-32.
38. Barnabei VM, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain IR. Flow cytometric evaluation of epithelial ovarian cancer. Am J Obstet Gynecol 1990;162:1584-92.